Table 2 Clinical information from the included studies.
First author, target disease | N (LCT arm) | No. of oligomets. (LCT arm) | Site (LCT arm) | Modality of LCT (LCT arm) | N (control arm) | No. of oligomets. (control arm) | Site (control arm) | Modality of control (control arm) | OS (LCT arm vs. control arm) 1/2-year rate | P value | PFS (LCT arm vs. control arm) 1/2-year rate | p Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
He, NSCLC | 11 | 1 (60%); 2 (40%) | Lung 100% | Resection of mets. and/or CTx | 10 | N/A | Lung 100% | CTx | 100/70% vs. 80/40% | 0.026 | ||
Iyengar, NSCLC | 14 | 2 (50%); 3–4 (28.6%) | Lung or mediastinum >70% | SBRT and CTx | 15 | 2 (40%); 3–4 (33%) | Lung or mediastinum >70% | CTx | 1 year: 35.7 vs. 13.3% | 0.01 | ||
Sheu, NSCLC | 60 | Mean 1.28 | Brain (~50%) | Conventional RTx (76%) | 14 | Mean 1.23 | Brain (~50%) | CTx | 83.3/58.3% vs. 35.7/0% | <0.01 | 1 year: 46.7 vs. 18.2% | <0.01 |
Yano, NSCLC | 44 | Surgery or RTx and/or CTx | 49 | CTx or SOC | 77.3/61.4% vs. 46.9/24.5% | <0.05 | ||||||
Frost, NSCLC | 90 | 1 (85%); 2 (8%) | Brain 57%; bone 10%; lung 9% | Lobectomy, CCRT, SBRT and 79% received CTx | 90 | 1 (76%); 2 (14%) | Brain 32%; bone 22%; lung 21% | CTx (96%) | 92.2/76% vs. 81.9/45.9% | <0.001 | 67.8/52.2% vs. 31/8.9% | <0.001 |
Gomez, NSCLC | 25 | 0–1 (68%); 2–3 (32%) | Brain 28%; other 72% | RTx or surgery and standard maintenance | 24 | 0–1 (62%); 2–3 (38%) | Brain 25%; other 75% | Standard maintenance | 84/68% vs. 62.5/45.8% | 0.017 | 52/28% vs. 20.8/12.5% | 0.022 |
Gray, NSCLC | 38 | 1 (50%); 2–4 (50%) | Brain 100% | Thoracic surgery or RTx, brain RTx, and CTx | 28 | 1 (50%); 2–4 (50%) | Brain 100% | CTx and/or Brain RTx | 71/54% vs. 46/26% | <0.001 | ||
Hu, NSCLC | 143 | 1–3 (81%); 4–5 (19%) | Brain 44%; bone 35% | Surgery and/or radiotherapy and TKI | 88 | 1–3 (83%); 4–5 (17%) | Bone 42%; lung 33% | CTx (TKI) | 95.3/72.1% vs. 84.1/40.9% | 0.001 | 60.7/18.6% vs. 33.3/10.8% | <0.001 |
Song, NSCLC | 35 | 1 (46%); 2 (29%); 3-5 (26%) | Lung 57%; bone 40%; liver 30% | Surgery or RTx and CTx | 35 | 1 (23%); 2 (40%); 3–5 (37%) | Lung 60%; bone 54% | CTx | 51.4/28.6% vs. 31.4/5.7% | 0.002 | ||
Xu Q, NSCLC | 51 | 1 (49%); 2–3 (51%) | Surgery or RTx after TKI | 39 | 1 (41%); 2–3 (51.3%) | CTx (TKI) | <0.001 | 86.3/25.6% vs. 70.5/0% | <0.001 | |||
Ni, NSCLC | 34 | 1–3 (85%); 4–5(15%) | Lung 40%; liver 23%; adrenal gland 16% | TKI and MWA | 52 | 1–3 (89%); 4–5 (11%) | Lung (32%); bone (23%); liver (20%) | CTx (TKI) | 94.1/67.6% vs. 90.3/46.2% | 0.04 | 88.2/23.5% vs. 61.5/0% | 0.02 |
Shang, NSCLC (postop) | 105 | 1 (73%); 2–5 (27%) | LN 46%; brain 24%; lung 19% | RTx or RFA and/or CTx | 47 | 1 (72%); 2–5 (28%) | LN (72%) lung (32%) | CTx or BSC | 1 year: 72.4 vs. 72.3% | 0.519 | 1 year: 40.9 vs. 29.8% | 0.006 |
Gore, SCLC (extended) | 44 | 1 (32%); 2–4 (68%) | Adrenal 25%; distant LN 23%: liver 23% | PCI and cRTx | 42 | 1 (41%); 2–4 (60%) | Distant LN 31%; Bone 26%; Liver 24% | PCI | 1 year: 50.8 vs. 60.1% | 0.21 | 1 year: 23.9 vs. 20.5% | 0.01 |
Xu SCLC (extended) | 22 | RTx and CTx | 22 | CTx | 72.7/25.2% vs. 18.2/12.7% | 0.002 | 40.9/19.3% vs. 9.1/4.8% | 0.006 | ||||
Bouman-Wammes, prostate | 43 | 1 (81%); 2 (14%) | LN 77%; bone 21% | SBRT | 20 | 1 (45%); 2 (40%) | LN 65%; Bone 35% | Active surveillance | 72.1/35.8% vs. 22.6/0% | <0.001 | ||
Lan, prostate | 35 | 1 (26%) 2 (37%) 3 (20%) | Bone 100% | Prostatectomy and ADT | 76 | 1 (8%) 2 (32%) 3 (30%) | Bone 100% | ADT | CSS 3/5 years: 90.8/63.6% vs. 87.9/74.9% | 0.773 | 82.8/62.8% vs. 65.8/38.2% | 0.184 |
Ost, prostate | 31 | 1 (58%); 2 (19%); 3 (22%) | LN 55%; non-nodal 45% | SBRT (81%) or resection | 31 | 1 (29%); 2 (32%); 3 (39%) | LN 55%; non-nodal 45% | Active surveillance | 70.9/45.2% vs. 64.5/32.3% | 0.11 | ||
Steuber, prostate | 165 | Pelvic LN ~90% | PLND or SBRT and ADT | 494 | Pelvic LN ~90% | ADT | OS 3/5 years: 99.2/98.7 vs. 98.2/95.4% | 0.23 | ||||
Parker, prostate | 410 | Bone 76%; distant LN 36% | RT and ADT | 409 | Bone 76%; distant LN 34% | ADT | OS 1/2/3 years: 98.8/92.5/82.6 vs. 96.7/87.7/74.8% | 0.007 | 89.6/72.8% vs. 86.3/69.6% | 0.033 | ||
Tsumura, prostate | 22 | Bone or pelvic LN | Metastatic RTx, prostate brachy, and HTx | 18 | Bone or pelvic LN | Prostate brachy and HTx | 94.4/88.9% vs. 95.5/73.3% | 0.0269 | ||||
Giessen, colorectal | 38 | 1 (95%) | Liver 100% | Hepatic resection and CTx | 215 | 1 (100%) | Liver 100% | CTx | 97.4/89.5% vs. 68/37.6% | <0.001 | 63.2/36.8% vs. 21.2/5.2% | <0.001 |
Ruer, colorectal | 60 | 1–3 (48%); 4–6 (30%); 7–9 (22%) | Liver 100% | RFA, surgery and/or CTx | 59 | 1–3 (31%); 4–6 (46%); 7–9 (24%) | Liver 100% | CTx | 91.7/75% vs. 89.8/74.5% | 0.01 | 58.3/35% vs. 40.7/20.3% | 0.005 |
Ruo, colorectal | 127 | 1 (68%); 2 (26%); 3 (6%) | Liver 56% | Bowel surgery and CTx | 103 | 1 (53%); 2 (30%); 3 (17%) | Liver 41% | CTx (83.5%) | 63.8/25% vs. 35.9/6% | <0.001 | ||
Palma, multiple | 66 | 1 (46%); 2 (29%); 3(18%) | Lung 43%; bone 35% | SBRT and/or standard CTx | 33 | 1 (36%); 2 (40%); 3 (18%) | Lung 53%; bone 31% | CTx | 84.3/69.7% vs. 87.4/60.6% | 0.09 | 54.5/36.4% vs. 22.7/15.2% | 0.0012 |
Chen Y, esophagus | 196 | CCRT | 265 | CTx | 72.8/27.2% vs. 63.5/17.5% | 0.056 | 27.6/4.7% vs. 21.9/0.9% | 0.002 | ||||
Depypere, esophagus | 10 | Lung 50%; adrenal 20% | Esophagectomy ± lung metastatectomy | 10 | Liver 50%; brain 30% | CTx | 80/40% vs. 50/10% | 0.042 | ||||
Chen J, HCC | 34 | Lung 100% | TACE, RFA, resection, and sorafenib | 34 | Lung 100% | Sorafenib | 67.6/47% vs. 35.3/23.5% | 0.015 | (TTP) 11.8/0% vs. 0/0% | 0.009 | ||
Pan, HCC | 46 | Mean 2.22 ± 1.35 | LN 100% | RFA and BSC or sorafenib | 46 | Mean 2.74 ± 1.37 | LN 100% | BSC or sorafenib | 58.3%/11.7% vs. 17.9/0% | 0.001 | ||
Morino, bile duct | 33 | Median 1 (1–-3) | Liver 39%; LN 27%; lung 12% | Surgery, RT, RFA, TACE, and/or CTx | 34 | Median 1 (1–3) | Local 35%; liver 29%; LN 21% | CTx or BSC | 97/84.8% vs. 64.7/20.5% | <0.001 | ||
Schulz, head and neck | 37 | 1 (70%); 2–3 (16%) | Lung 59%; bone 22% | RTx or resection and/or CTx | 10 | 1 (100%) | Lung 90% | CTx or BSC | 67.6%/51.3% vs. 20%/10% | NA | ||
Falk, sarcoma | 164 | Lung 51%; liver 7% | RTx, RFA, OP ± CTx | 117 | Lung 69%; liver 7% | CTx in majority | 79.6/63.6% vs. 52.3/36.3% | <0.0001 |
